FDA Approves Tremfya for Active Crohn Disease in Adults

MONDAY, March 24, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for adult patients with moderately to severely active Crohn disease.

Javascript is required for you to be able to read premium content. Please enable it in your browser settings..